Wednesday Trader Radar (GENZ, ALXA, GNW, YHOO, ERTS, ARNA, AXP)
Genzyme Corp. (NASDAQ: GENZ) won a recommendation from the FDA advisory committee unanimously recommending approval of Genzyme’s Synvisc-one for osteoarthritis in the knee. Shares are indicated up almost 3% at $65.00. Just keep in mind that its market cap is now $17 billion.
Alexza Pharmaceuticals Inc. (NASDAQ: ALXA) announced that its AZ-004, an inhalation [...]
VS Investor RSS Feed
